EP1122186A1 - Behälter für pharmazeutische Produkte mit zwei gesonderten, unstabilen Komponenten - Google Patents

Behälter für pharmazeutische Produkte mit zwei gesonderten, unstabilen Komponenten Download PDF

Info

Publication number
EP1122186A1
EP1122186A1 EP20000204366 EP00204366A EP1122186A1 EP 1122186 A1 EP1122186 A1 EP 1122186A1 EP 20000204366 EP20000204366 EP 20000204366 EP 00204366 A EP00204366 A EP 00204366A EP 1122186 A1 EP1122186 A1 EP 1122186A1
Authority
EP
European Patent Office
Prior art keywords
component
upper container
combination
pharmaceutically active
cap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20000204366
Other languages
English (en)
French (fr)
Inventor
Michael Van Wie Bergamini
Gemma Torrella Cabello
Jose Alberto Vallet Mas
Nuria Carreras Perdiguer
David W. Stroman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of EP1122186A1 publication Critical patent/EP1122186A1/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093—Containers having several compartments for products to be mixed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/24—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
    • B65D51/28—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
    • B65D51/2807—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container
    • B65D51/2814—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it
    • B65D51/2842—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it said element being provided with a preformed weakened line
    • B65D51/285—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it said element being provided with a preformed weakened line ruptured by a sharp element, e.g. a cutter or a piercer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/202—Separating means
    • A61J1/2027—Separating means having frangible parts

Definitions

  • the present invention generally pertains to the delivery of unstable liquids. More particularly, but not by way of limitation, the present invention pertains to the delivery of unstable pharmaceutical preparations to the eye, ear, or nose.
  • Topical pharmaceutical preparations for the eye, ear, and nose are typically formulated as a liquid solution or suspension.
  • certain topical preparations have individual components that, if mixed, have a shelf life of only a few weeks. Typically, one of the components is in a powdered form, and the other component is in a liquid form.
  • Such topical pharmaceutical preparations were initially packaged with the unstable components in two separate containers. The components were then dispensed in certain specified amounts from their separate containers into a third container and mixed just prior to delivery. Delivery of the mixed preparation was typically accomplished via a conventional dropper. Because of the inconvenience of and the risk of user non-compliance with such two container preparations, various containers were developed having two, separate compartments for the unstable components. Such containers could be manipulated by a user to mix the components just prior to delivery and then deliver the mixed preparation via an integrated nozzle.
  • U.S. Patent Nos. 5,474,209 and 5,782,345 provide examples of such containers.
  • One aspect of the present invention is a device for the delivery of a pharmaceutical preparation having a first component and a second component.
  • the device includes an upper container for receiving the first component and having a bottom.
  • the first component includes an unstable anti-infective agent.
  • the device also includes a lower container for receiving a second component.
  • the second component includes a liquid carrier for the first component.
  • the device further includes a tubular sleeve movably disposed within the upper container and a cap rotationally coupled to the upper container. When the cap is screwed onto the upper container, the tubular sleeve tears the bottom of the upper container to place the first component in communication with the second component.
  • the device in another aspect, includes an upper container for receiving a first component and having a bottom.
  • the first component includes a first pharmaceutically active agent.
  • the device also includes a lower container for receiving a second component unstable in the first component.
  • the second component includes a second pharmaceutically active agent.
  • the device further includes a tubular sleeve movably disposed within the upper container and a cap rotationally coupled to the upper container. When the cap is screwed onto the upper container, the tubular sleeve tears the bottom of the upper container to place the first component in communication with the second component.
  • FIGS. 1-10 of the drawings like numerals being used for like and corresponding parts of the various drawings.
  • Device 10 for the delivery of unstable liquids is shown according to a preferred embodiment of the present invention.
  • Device 10 is preferably used to deliver topical pharmaceutical preparations to the eye, car, or nose.
  • device 10 is described hereinafter as a device for the delivery of topical pharmaceutical preparations.
  • device 10 generally includes a lower container 12, and upper container 14, a tubular sleeve or member 16, a cap 18, and a safety seal 19.
  • upper container 14 is coupled to lower container 12
  • tubular sleeve 16 is disposed within and coupled to upper container 14
  • cap 18 covers tubular sleeve 16 and is removably coupled to upper container 14
  • safety seal 19 is disposed around upper container 14 below cap 18.
  • Cap 18 and safety seal 19 are shown in dashed lines in FIG. 4 for clarity of illustration.
  • the various portions of device 10 are preferably formed from conventional polymeric materials.
  • lower container 12 is formed of low density polyethylene
  • upper container 14 is formed of high density polyethylene
  • tubular sleeve 16 is formed of Zylar, a copolymer available from NOVA Chemicals of Leominster, Massachusetts
  • cap 18 is formed of polypropylene.
  • Upper container 14 has a reservoir 20 for holding a first component 22 of a pharmaceutical preparation.
  • Lower container 12 has a reservoir 24 for holding a second component 26 of a pharmaceutical preparation.
  • first component 22 is unstable in second component 26 after a certain time period, which may be as long as several weeks or months, or as short as a few hours or minutes.
  • Lower container 12 includes a hollow neck 28 that includes two ring shaped edges 30 and 32. Stria 34 are located on edges 30 and 32. A shoulder 36 is located at the junction of neck 28 and reservoir 24. Sealing rings 37 are located on the internal surface of neck 28 above shoulder 36.
  • upper container 14 includes a surface 82 that mates with sealing rings 37 of lower container 12 to prevent leakage of second component 26 from reservoir 24 or entry of air into reservoir 24.
  • Upper container 14 also includes a flap 38 that surrounds neck 28 of lower container 12.
  • flap 38 includes two ring shaped ribs 40 and 42 disposed on the internal surface 44 of flap 38 and for mating with edges 30 and 32 of lower container 12.
  • Stria 46 run vertically along internal surface 44 from rib 40 to the internal surface of shoulder 48.
  • stria 46 also run horizontally and radially along the internal surface of shoulder 48 toward the longitudinal axis of upper container 14.
  • stria 34 of edges 30 and 32 couple with stria 46 to prevent upper container 14 and lower container 12 from rotating relative to each other.
  • a plurality of sawteeth 50 are disposed on the external surface of shoulder 48.
  • sawteeth 50 mate with flexible wings 52 to removably couple safety seal 19 to upper container 14.
  • Safety seal 19 has a ring-shaped geometry with a perforation at connecting point 58.
  • Safety seal 19 has an axial wing 56 that is connected to the remainder of seal 19 at a connecting point 59.
  • Upper container 14 also has a neck 55 having external threads 56 for mating with internal threads 60 of cap 18, as is best shown in FIG. 8.
  • upper container 14 has bottom 62 that is tearable along a perforated line 64 disposed about the periphery of bottom 62.
  • Tubular sleeve 16 includes a hollow body 64 having a truncated cone-shaped portion 66 on one end and a helicoidal edge 68 on an opposite end.
  • Truncated cone-shaped portion 66 has a internal channel 70 terminating in a reverse truncated cone-shaped hole 72 that serves as the nozzle or dropper to dispense a pharmaceutical preparation from device 10.
  • truncated cone-shaped portion 66 may be modified to include a conventional "Luer Lok" that complies with Luer Taper Specification 70.1 of the American Standards Association and that allows coupling to a syringe, cannula, or other conventional medical instruments.
  • Helicoidal edge 68 preferably has a small horizontal section 74.
  • Tubular sleeve 16 also includes a first sealing ring 76 and a second sealing ring 78 disposed on the external surface of body 64. Sealing rings 76 and 78 mate with internal surface 84 of reservoir 20 of upper container 14 to prevent leakage of first component 22 from reservoir 20 or entry of air into reservoir 20. Sealing ring 78 is especially useful in preventing such leakage or entry when first component 22 is a liquid. As shown in FIG. 8, cap 18 preferably has a member 80 that seals hole 72 when cap 18 is screwed onto upper container 14.
  • reservoir 20 of upper container 14 holds first component 22 of a pharmaceutical preparation.
  • Reservoir 24 of lower container 12 holds a second component 26 of a pharmaceutical preparation.
  • first component 22 and second component 26 may be the unstable components of a liquid other than a pharmaceutical preparation.
  • First component 22 preferably comprises an ophthalmically effective amount of one or more pharmaceutically active agents, or an otorhinolaryngologically effective amount of one or more pharmaceutically active agents.
  • First component 22 may also comprise an ophthalmically acceptable carrier or an otorhinolaryngologically acceptable carrier, respectively.
  • ophthalmically acceptable carrier refers to any substance or combination of substances that are non-reactive with the pharmaceutically active agent and suitable for administration to a user's eye.
  • otorhinolaryngologically acceptable carrier refers to any substance or combination of substances that are non-reactive with the pharmaceutically active agent and suitable for administration to a user's ear or nose.
  • Solubilizers and stabilizers are deemed to be non-reactive.
  • an ophthalmically acceptable carrier or an otorhinolaryngologically acceptable carrier may comprise any combination of preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, solubilizers, stabilizers, pH adjusters, tonicity agents, fillers, and water.
  • Preferred pharmaceutically active agents are anti-infectives, including, without limitation, antibiotics, antivirals, and antifungals; steroidal and non-steroidal anti-inflammatory agents; and combinations of the foregoing.
  • Preferred antibiotics include, without limitation, trimcthoprims; polymyxin B sulfate; beta-lactams, including, without limitation, cephalosporins, penicillins, thienamycins, penems, cephems, and trinems; oxazolidinones; macrolides, including without limitation, erythromycins and erythromycin lactobionate; keytolides; tetracyclines, including, without limitation, chlortetracylcines and chlortetracycline hydrochloride; and pristinomycins.
  • Preferred steroidal anti-inflammatory agents include, without limitation, dexamethasone and dexamethasone phosphate.
  • First component 22 may be in a powder or liquid form.
  • Second component 26 preferably comprises an ophthalmically effective amount of one or more pharmaceutically active agents, or an otorhinolaryngologically effective amount of one or more pharmaceutically active agents. Second component 26 may also comprise an ophthalmically acceptable carrier or an otorhinolaryngologically acceptable carrier, respectively. Second component 26 preferably utilizes the same preferred pharmaceutically active agents as first component 22. Alternatively, second component 26 may comprise an ophthalmically or otorhinolaryngologically acceptable carrier but no pharmaceutically active agent. In this case, second component 26 acts as a diluent to first component 22.
  • first component 22 may comprise an ophthalmically or otorhinolaryngologically acceptable carrier but no pharmaceutically active agent
  • second component 26 may comprise one or more pharmaceutically active agents.
  • first component 22 acts as a diluent for second component 26.
  • Device 10 is assembled using conventional techniques.
  • Device 10 is preferably sterilized by conventional ganuna radiation methods if such methods do not inhibit the efficacy of the pharmaceutical preparation.
  • device 10 may be sterilized by conventional Eto methods, if necessary.
  • device 10 is in a first position in which components 22 and 26 are unmixed.
  • a user first moves axial wing 56 of safety seal 19 radially outward, breaking connecting point 59.
  • the user then holds axial wing 56 and rotates safety seal 19 about a longitudinal axis of device 10, causing sawteeth 50 of upper container 14 to engage flexible wings 52 of safety seal 19.
  • Such rotation splits safety seal 19 at connection point 58.
  • the user can then remove safety seal 19 from device 10.
  • sealing rings 76 and 78 mate with internal surface 84 of upper container 14 to prevent leakage of the components from reservoirs 20 and 24 or entry of air into the reservoirs.
  • the mixed pharmaceutical preparation may be dispensed into the eye, ear, or nose of a user by squeezing on the external surface of lower container 12 so as to force the mixture through nozzle 66 of tubular sleeve 16.
  • member 80 seals hole 72.
  • Device 10 may be used to deliver an ophthalmic or otic pharmaceutical preparation comprising a first component 22 that is a solution having dexamethasone phosphate as a pharmaceutically active agent and a second component 26 that is a solution having both trimethoprim and polymyxin B sulfate as pharmaceutically active agents.
  • First component 22 preferably has a volume of 1 ml.
  • the composition of first component 22 is 0.5 % weight/volume dexamethasone phosphate, 0.01 % weight/volume benzalkonium chloride, 0.25 % weight/volume polysorbate 80, 12.20 % weight/volume trisodium citrate 2H 2 O, a quantity of citrate acid sufficient to adjust the pH of first component 22 to 7.8, and a quantity of water sufficient to adjust the volume of first component 22 to 100%.
  • Second component 26 preferably has a volume of 4 ml.
  • the composition of second component 26 is 0.125 % weight/volume trimethoprim, 1.25 mill. I.U.
  • first component 22 and second component 26 exhibit good stability results for up to twenty-four months.
  • an effective antibiotic/steroid pharmaceutical preparation may be delivered to the eye or the ear.
  • Device 10 may be used to deliver an ophthalmic pharmaceutical preparation comprising a first component 22 that is a powder having chlortetracycline hydrochloride as a pharmaceutically active agent and a second component 26 that acts as a ophthalmically acceptable carrier for first component 22.
  • First component 22 preferably has a weight of 100 mg.
  • the composition of first component 22 is 25 % weight/weight chlortetracycline hydrochloride and a quantity of lactose sufficient to adjust the weight of first component 22 to 100%.
  • the exact quantity of lactose may vary slightly according to the potency of the chlortetracycline hydrochloride.
  • Second component 26 preferably has a volume of 5 ml.
  • the composition of second component 26 is 0.03 % weight/volume nipagin M, 0.02 % weight/volume nipasol M, 0.54 % weight/volume sodium chloride, 0.75 % weight/volume sodium tetraborate 10 H 2 O, 0.2 % weight/volume polyvinylpyrrolidone, and a quantity of purified water sufficient to adjust the volume of second component 26 to 100 %.
  • first component 22 and second component 26 exhibit good stability results for up to twenty-four months.
  • an effective antibiotic pharmaceutical preparation may be delivered to the eye.
  • Device 10 may be used to deliver an ophthalmic pharmaceutical preparation comprising a first component 22 that is a powder having erythromycin lactobionate as a pharmaceutically active agent and a second component 26 that acts as a ophthalmically acceptable carrier for first component 22.
  • First component 22 contains 50 mg of erythromycin lactobionate.
  • Second component 26 preferably has a volume of 5 ml.
  • the composition of second component 26 is 0.050 % weight/volume polysorbate 80, 3 % weight/volume sodium citrate 2 H 2 O, 0.005 % weight/volume benzalkonium chloride, and a quantity of citric acid (pH 8.2) sufficient to adjust the volume of second component 26 to 100 %.
  • first component 22 and second component 26 exhibit good stability results for up to twenty-four months.
  • an effective antibiotic pharmaceutical preparation may be delivered to the eye.
  • the polysorbate 80 contained in second component 26 avoids or minimizes benzalkonium chloride instability due to gamma radiation sterilization and advantageously allows device 10 to be sterilized by conventional gamma radiation methods instead of Eto methods.
  • the present invention is illustrated herein by example, and various modifications may be made by a person of ordinary skill in the art.
  • the geometries of the device and its individual components may be modified from the geometries described for the preferred embodiments.
  • the device may be used with unstable pharmaceutically active agents other than anti-infectives and anti-inflammatories, or with other unstable liquids.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
EP20000204366 1999-12-20 2000-12-07 Behälter für pharmazeutische Produkte mit zwei gesonderten, unstabilen Komponenten Withdrawn EP1122186A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17268599P 1999-12-20 1999-12-20
US172685P 1999-12-20

Publications (1)

Publication Number Publication Date
EP1122186A1 true EP1122186A1 (de) 2001-08-08

Family

ID=22628753

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20000204366 Withdrawn EP1122186A1 (de) 1999-12-20 2000-12-07 Behälter für pharmazeutische Produkte mit zwei gesonderten, unstabilen Komponenten

Country Status (11)

Country Link
US (1) US20020020636A1 (de)
EP (1) EP1122186A1 (de)
KR (1) KR20010067406A (de)
AR (1) AR031228A1 (de)
BR (1) BR0005936A (de)
CO (1) CO5300435A1 (de)
DZ (1) DZ3170A1 (de)
HK (1) HK1040679A1 (de)
MA (1) MA25291A1 (de)
TN (1) TNSN00244A1 (de)
UY (1) UY26486A1 (de)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056402A1 (en) * 2003-12-09 2005-06-23 Martin Bochtler System for combining liquids
WO2005049430A3 (en) * 2003-11-22 2005-08-04 Jung-Min Lee Cap with storage chamber for secondary material and product with the same
WO2005044430A3 (en) * 2003-11-10 2005-08-04 Jeong-Min Lee Method and structure for mixing different materials in the pouch container
US7210575B2 (en) 2002-09-26 2007-05-01 Boehringer Ingelheim International Gmbh Two-component packaging unit
WO2011060456A1 (en) * 2009-11-10 2011-05-19 Ewan Dirk Kromhout An accessory for a container
ITTO20110244A1 (it) * 2011-03-21 2011-06-20 Bisio Progetti Spa Sistema di miscelazione ed erogazione.
KR101133406B1 (ko) * 2003-11-22 2012-04-09 이선희 별도의 내용물 저장공간을 갖고 있는 병뚜껑
KR101177931B1 (ko) 2004-01-13 2012-08-28 이선희 별도의 내용물 저장공간을 갖고 있는 병뚜껑
WO2011124891A3 (en) * 2010-04-07 2012-12-20 The Enterprise Cradle Limited Connector system for medical fluid administration
WO2016127222A1 (en) * 2015-02-13 2016-08-18 Sinaclear Ip Pty Ltd Fluid delivery apparatus
AU2015264853B2 (en) * 2010-04-07 2017-07-27 The Enterprise Cradle Limited Connector system for medical fluid administration
EP3288518A4 (de) * 2015-05-01 2018-12-12 Sun Pharmaceutical Industries Limited Verpackung mit zwei kammern für retard-suspensionszusammensetzungen
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US10285908B2 (en) 2014-07-30 2019-05-14 Sun Pharmaceutical Industries Ltd Dual-chamber pack
US11504345B2 (en) 2014-05-01 2022-11-22 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE477193T1 (de) * 2003-03-15 2010-08-15 Brin Tech Internat Ltd Verpackung für arzneimittel
US6910573B2 (en) 2003-04-24 2005-06-28 David M. Deans Dual container bottle
HRPK20030525B1 (en) * 2003-06-26 2004-08-31 Cedevita D O O Bottle cap - container and dosage device of ingredients for quick preparation of beverages
WO2005091725A2 (en) * 2004-03-08 2005-10-06 Jeong-Min Lee Structure of cap having storing space
KR100597217B1 (ko) * 2004-11-23 2006-07-06 조영국 첨가제 첨가 가능한 위조방지 위생이중캡
US8151985B2 (en) 2007-06-22 2012-04-10 Owoc Greg J Containers for storing at least two substances for subsequent mixing
US20090194533A1 (en) * 2008-02-04 2009-08-06 Lizerbram Eric K Closure with additive reservoir
US20110011822A1 (en) * 2009-07-16 2011-01-20 Genmont Biotech Incorporation Bottle cap
ITMI20110054U1 (it) * 2011-02-16 2011-05-18 Federico Thoman Bottiglia con tappo dispensatore
JP5736240B2 (ja) * 2011-06-08 2015-06-17 伸晃化学株式会社 薬液容器
US9145221B2 (en) * 2012-03-20 2015-09-29 La Prairie, Inc. Convertible two compartment container
US20160200500A1 (en) * 2015-01-07 2016-07-14 Lavico Inc. L-Ascorbic Acid Formulations and Methods of Use for Skin Care
ITUB20159655A1 (it) 2015-12-23 2017-06-23 Bormioli Rocco Spa Capsula di sicurezza di un contenitore.
US10238803B2 (en) * 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
WO2018118845A1 (en) * 2016-12-20 2018-06-28 Elc Management Llc Fresh cosmetic composition delivery system
US10640275B2 (en) * 2017-06-12 2020-05-05 Bio-Techne Corportion Dual chamber storage device
IT201800002518A1 (it) * 2018-02-08 2019-08-08 Bormioli Pharma Spa Capsula di chiusura di un contenitore
IT201800002519A1 (it) * 2018-02-08 2019-08-08 Bormioli Pharma Spa Chiusura di un contenitore
US10407223B1 (en) * 2018-03-29 2019-09-10 Repligen Corporation Device and draping method for facilitating introduction of a non-sterile container into a sterile environment
US11279528B2 (en) * 2019-09-23 2022-03-22 Lyvecap Llc Container cap and compounds
US11905097B2 (en) * 2020-07-10 2024-02-20 o6 Innovations Inc. Multi-compartment beverage container for dispensing a mixed beverage
US20230039707A1 (en) * 2021-08-04 2023-02-09 Andrew Jhonnie Spencer Self-heating or self-cooling system and method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474209A (en) 1992-07-02 1995-12-12 Laboratorios Cusi, S.A. Pharmaceutical product container with two separate substances and a mixing device and dosed dispensation
FR2723695A1 (fr) * 1994-08-17 1996-02-23 Nathon Roger Solution pour instillations nasales
EP0778221A1 (de) * 1995-12-04 1997-06-11 Laboratorios Cusi, S.A. Behälter für pharmazeutische Produkte mit zwei gesonderten Komponenten, mit Mitteln zu deren Mischung, dosierter Ausgabe und Verfertigungsverfahren dafür

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474209A (en) 1992-07-02 1995-12-12 Laboratorios Cusi, S.A. Pharmaceutical product container with two separate substances and a mixing device and dosed dispensation
FR2723695A1 (fr) * 1994-08-17 1996-02-23 Nathon Roger Solution pour instillations nasales
EP0778221A1 (de) * 1995-12-04 1997-06-11 Laboratorios Cusi, S.A. Behälter für pharmazeutische Produkte mit zwei gesonderten Komponenten, mit Mitteln zu deren Mischung, dosierter Ausgabe und Verfertigungsverfahren dafür
US5782345A (en) 1995-12-04 1998-07-21 Laboratorios Cusi, S.A. Pharmaceutical bottle of two separate substances with mixing device, dosed application and assembly process thereof

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7210575B2 (en) 2002-09-26 2007-05-01 Boehringer Ingelheim International Gmbh Two-component packaging unit
WO2005044430A3 (en) * 2003-11-10 2005-08-04 Jeong-Min Lee Method and structure for mixing different materials in the pouch container
US7617929B2 (en) 2003-11-10 2009-11-17 Lee Jeong-Min Method and structure for mixing different materials in a pouch container
WO2005049430A3 (en) * 2003-11-22 2005-08-04 Jung-Min Lee Cap with storage chamber for secondary material and product with the same
US7546919B2 (en) 2003-11-22 2009-06-16 Jung Min Lee Cap with storage chamber for secondary material and the product with the same
AU2004291446B2 (en) * 2003-11-22 2011-02-03 Jung-Min Lee Cap with storage chamber for secondary material and product with the same
KR101133406B1 (ko) * 2003-11-22 2012-04-09 이선희 별도의 내용물 저장공간을 갖고 있는 병뚜껑
WO2005056402A1 (en) * 2003-12-09 2005-06-23 Martin Bochtler System for combining liquids
KR101177931B1 (ko) 2004-01-13 2012-08-28 이선희 별도의 내용물 저장공간을 갖고 있는 병뚜껑
WO2011060456A1 (en) * 2009-11-10 2011-05-19 Ewan Dirk Kromhout An accessory for a container
JP2018183603A (ja) * 2010-04-07 2018-11-22 ザ エンタープライズ クレイドル リミティド 医療用流体投与のためのコネクタシステム
EA026420B1 (ru) * 2010-04-07 2017-04-28 Зе Энтерпрайз Крэйдл Лимитед Соединительная система для введения медицинской текучей среды
CN102985046A (zh) * 2010-04-07 2013-03-20 克雷德尔企业有限公司 用于药物流体给药的连接器系统
JP2013523303A (ja) * 2010-04-07 2013-06-17 ザ エンタープライズ クレイドル リミティド 医療用流体投与のためのコネクタシステム
AU2011236650B2 (en) * 2010-04-07 2015-09-03 The Enterprise Cradle Limited Connector system for medical fluid administration
GB2480989B (en) * 2010-04-07 2016-05-04 The Entpr Cradle Ltd Connector system for medical fluid administration
CN102985046B (zh) * 2010-04-07 2016-06-22 克雷德尔企业有限公司 用于药物流体给药的连接器系统
US9375560B2 (en) 2010-04-07 2016-06-28 The Enterprise Cradle Limited Connector system for medical fluid administration
US11607534B2 (en) 2010-04-07 2023-03-21 The Enterprise Cradle Limited Connector system for medical fluid administration
EP3072493A1 (de) * 2010-04-07 2016-09-28 The Enterprise Cradle Limited Anschlusssystem zur verabreichung von medizinischen flüssigkeiten
JP2016185331A (ja) * 2010-04-07 2016-10-27 ザ エンタープライズ クレイドル リミティド 医療用流体投与のためのコネクタシステム
WO2011124891A3 (en) * 2010-04-07 2012-12-20 The Enterprise Cradle Limited Connector system for medical fluid administration
AU2015264853B2 (en) * 2010-04-07 2017-07-27 The Enterprise Cradle Limited Connector system for medical fluid administration
EP3398582A1 (de) * 2010-04-07 2018-11-07 The Enterprise Cradle Limited Anschlusssystem zur verabreichung von medizinischen flüssigkeiten
US10485965B2 (en) 2010-04-07 2019-11-26 The Enterprise Cradle Limited Connector system for medical fluid administration
ITTO20110244A1 (it) * 2011-03-21 2011-06-20 Bisio Progetti Spa Sistema di miscelazione ed erogazione.
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US11504345B2 (en) 2014-05-01 2022-11-22 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US10285908B2 (en) 2014-07-30 2019-05-14 Sun Pharmaceutical Industries Ltd Dual-chamber pack
CN109310570A (zh) * 2015-02-13 2019-02-05 思纳可利尔知识产权私人有限公司 流体输送设备
WO2016127222A1 (en) * 2015-02-13 2016-08-18 Sinaclear Ip Pty Ltd Fluid delivery apparatus
EP3288518A4 (de) * 2015-05-01 2018-12-12 Sun Pharmaceutical Industries Limited Verpackung mit zwei kammern für retard-suspensionszusammensetzungen

Also Published As

Publication number Publication date
BR0005936A (pt) 2001-09-04
DZ3170A1 (fr) 2004-12-28
MA25291A1 (fr) 2001-12-31
CO5300435A1 (es) 2003-07-31
HK1040679A1 (zh) 2002-06-21
UY26486A1 (es) 2001-07-31
US20020020636A1 (en) 2002-02-21
AR031228A1 (es) 2003-09-17
KR20010067406A (ko) 2001-07-12
TNSN00244A1 (fr) 2002-05-30

Similar Documents

Publication Publication Date Title
EP1122186A1 (de) Behälter für pharmazeutische Produkte mit zwei gesonderten, unstabilen Komponenten
US7213593B2 (en) Two-chamber cartridge for propellant-free metering aerosols
JP4416653B2 (ja) ２つのチャンバーを有するバイアルに収容された注射用医薬懸濁液
US2798488A (en) Syringe unit
JP2602614B2 (ja) 薬品コンテナ
US4244467A (en) Device for the extemporaneous preparation of a solution under sterile conditions
ES2350631T3 (es) Aparato y método para la reconstitución de un medicamento incluyendo un dispositivo de transferencia de fluido.
US6247617B1 (en) Single use container for dispensing separately housed sterile compositions
US6572256B2 (en) Multi-component, product handling and delivering system
JPH0226506B2 (de)
US4346820A (en) Apparatus for mixing and dispersing two substances under sterile conditions
JP2015504716A (ja) 拡径遠位注射器先端を有する注射器とともに使用するためのバイアルアダプタ
DE19847968A1 (de) Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
JPH0611286B2 (ja) 薬の容器及び分配システム
JP2000511445A (ja) 注入可能な医薬剤のための再調合装置
AU7661200A (en) Medicament dispenser
JP2002537949A (ja) シリンジ装置
WO2001046035A1 (en) Container with two compartments and a mixing device
GB2499567A (en) Collapsible container for mixing pharmaceutical composition
US20160030723A1 (en) Multi-Chamber Anesthetic Delivery System
JP3840774B2 (ja) 用時調製型薬液容器
EP0509754A2 (de) Abgabevorrichtung
JP2001502938A (ja) ２成分の別個の充填済みバレルを含むシリンジシステム
WO2002076373A1 (en) Twin chamber dispenser with twist valve
JPH11319028A (ja) 点眼剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20011214

AKX Designation fees paid

Free format text: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALCON, INC

17Q First examination report despatched

Effective date: 20021009

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030220

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1040679

Country of ref document: HK